Elaine Campbell
A retired senior executive with over 30 years of experience in the pharmaceutical and chemical industry, Elaine has broad commercial experience in sales and marketing, including early and pre-launch product development, product launch, and life cycle management. Her experience includes Global and North American roles. Elaine was the president of AstraZeneca Canada from 2012 to 2015.
Dan Suesskind
Dan Suesskind was the Global CFO of Teva Pharmaceuticals, a $45 billion market cap company, from 1987-2008. Among his achievements, Dan registered Teva on the NASDAQ, led multiple successful acquisitions, and raised over $6 billion in the U.S. During Dan’s tenure with Teva, sales rose from $28 million to $11 billion.
Mary Rotunno
Mary L. Rotunno, J.D. advises life sciences and health care companies as well as currently serves on the board of Vistagen, a late clinical-stage public biopharma company. She is past Board Chair at Momentum for Health, provider of mental health services in Silicon Valley. Over the past 10 years, she served as General Counsel and Member of the Executive Leadership Team at El Camino Health, a $1.4 billion revenue health care system. Before joining El Camino Health in early 2014, Ms. Rotunno spent over 11 years as Senior Counsel and Client Service Leader for Common Spirit Health, formerly Dignity Health, in San Francisco Bay Area. Prior to Dignity Health, she held various legal roles at Varian Medical Systems, Manatt, Phelps & Phillips, Golden Living, and Pillsbury Winthrop Shaw Pitman. Ms. Rotunno maintains NACD Directorship Certification and completed Stanford Directors’ College.
Craig Fraser
Craig Fraser has 34 years of experience as a leader in building and leading successful global biopharmaceutical businesses in both startups and running multi-billion dollar businesses in some of the largest companies across nearly all functions and aspects of biopharmaceuticals. After having held various executive positions at several top companies, Craig serves on two management boards including most recently as Chairman and CEO of publicly listed Windtree Therapeutics for the past eight years and for SaNOtize. He is also a veteran of both the U.S. Marine Corps and the U.S. Army.
Craig has a broad set of experiences in successful fundraising (including IPOs), developing and executing company and development strategies, business development mergers and licenses and managing execution and commercialization in various business situations marked by opportunities and significant challenges. He has built and led global business and operations in specialty biopharmaceuticals and med tech in areas such as Oncology, Rare Diseases, Cardiovascular, Immunology, Anti-Infectives and Hospital / Critical Care.
Kerry Liu
Kerry Liu has served as a Venture Investor at Horizons Ventures since 2022 where he is currently an active board director or observer at Syzygy, Fleet Aerospace, H2Pro, Zero Avia, HzO, and Promise Robotics. Prior to joining Horizons Ventures, Kerry spent a decade as a technology entrepreneur. He was an early employee and member of the management team at Strangeloop Networks which was acquired by Radware (RDWR). After Strangeloop, Kerry was the Founder & CEO of Rubikloud, a leading artificial intelligence start-up focused on the retail and CPG space. Rubikloud was acquired by Kinaxis (KXS.TO) in 2022. Post acquisition, Kerry served as a member of the executive management team at Kinaxis leading global product management & corporate development.
He graduated from The University of British Columbia with a Bachelor of Commerce, completed his Chartered Accountant designation at PwC and currently lives in Toronto Canada. Outside of Horizons, he is an active angel investor and advisor to a dozen start-ups.
Gilly Regev, PhD
Chief Strategy and Innovation Officer, SaNOtize Cofounder
Experienced biotech executive with hands-on experience in launching pharmaceutical enterprises.
Experienced biotech executive with hands-on experience in launching pharmaceutical enterprises.
For the past 30 years, Dr. Regev has been a leader in biochemistry and microbiology R&D. She has extensive experience in drug development, intellectual property development, and clinical trials, as well as early-stage biotech fundraising and licensing deals.
Since co-founding SaNOtize in 2017, Dr. Regev has led the company from early research to an approved product and revenue generation in a very short time. She has also successfully capitalized the company through a significant Series B funding round and non-dilutive funding. Prior to SaNOtize, Dr. Regev spent twelve years in the field of nitric oxide, including as Chief Scientific Officer for Bovicor, an animal health company, and Director of R&D at Nitric Solutions, Inc. She earned her PhD in Biochemistry from the Hebrew University of Jerusalem.
In 2022, Dr. Regev was featured as one of the Top 25 Women Leaders in Biotechnology by the Healthcare Technology Report and in 2021 won a YWCA Women of Distinction Award as Entrepreneur and Innovator of the Year. Dr. Regev is also part of the Vancouver Chapter of the Weizmann Institute and a member of the Canadian Antimicrobial Innovation Coalition Steering Committee.
Chris Miller, PhD, BA, RT
Chief Science Officer, SaNOtize Cofounder
A pioneer in nitric oxide technology and therapeutic research.
A pioneer in nitric oxide technology and therapeutic research.
Dr. Miller has 30 years of experience in nitric oxide (NO) research, drug and device development, and commercialization. He has served as CEO/CSO in nitric oxide biotech startup fundraising and out licensing, and has expertise in clinical trial design and execution, intellectual property, regulatory affairs, and management.
Among his contributions, which include more than 40 peer-reviewed papers, Dr. Miller characterized one of the antimicrobial mechanisms of action of NO and identified its effective dose against multiple microbes including bacteria, fungi, and viruses. Dr. Miller also worked on the design of two of the first three FDA-approved NO gas delivery devices, and designed and completed the first human clinical trial demonstrating that inhaled NO was safe in healthy adults as a potential inhaled antimicrobial strategy.
Dr. Miller was an assistant professor in the Faculty of Medicine, Respiratory & Infectious Diseases Divisions at the University of British Columbia, Canada. He holds a PhD in Experimental Medicine and degrees in Health Management and Respiratory Therapy.